Cardioasset Taurine

General characteristics. Structure:

Active ingredient: 500 mg of taurine in 1 tablet.

Auxiliary components: povidone, cellulose microcrystallic, croscarmellose sodium, calcium stearate, silicon dioxide colloid.

Pharmacological properties:

Pharmacodynamics. Taurine is a natural product of exchange of sulfur-containing amino acids: cysteine, Cysteaminum, methionine. Taurine possesses osmoregulatory and membranoprotektorny properties, positively influences phospholipidic structure of membranes of cells, normalizes exchange of calcium ions and potassium in cells. At taurine properties of a brake neurotransmitter are revealed, it possesses antistressorny action, can regulate release of gamma aminobutyric acid (GAMK), adrenaline, prolactin and other hormones, and also to regulate answers to them. Participating in protein synthesis of a respiratory chain in mitochondrions, taurine regulates oxidizing processes and shows antioxidant properties; influences enzymes, such as the tsitokhroma participating in metabolism of various xenobiotics.

Taurine improves metabolic processes in heart, a liver and other bodies and fabrics. At chronic diffusion diseases of a liver taurine increases a blood stream and reduces expressiveness of a cytolysis.

Drug Kardioaktiv Taurin at the cardiovascular insufficiency (CI) leads treatment to reduction of developments of stagnation in small and big circles of blood circulation: intracardiac diastolic pressure decreases, contractility of a myocardium (the maximum speed of reduction and relaxation, indexes of contractility and a relaxation) increases. Drug moderately reduces the arterial pressure (AP) at patients with arterial hypertension and practically does not influence the ABP level at patients with cardiovascular insufficiency with the lowered ABP.

The cardioasset Taurine reduces the by-effects arising at overdose of cardiac glycosides and blockers of "slow" calcium channels; reduces a hepatotoxic of antifungal drugs. Increases working capacity at heavy exercise stresses.

At a diabetes mellitus approximately in 2 weeks after the beginning of administration of drug Kardioaktiv Tuarin decreases concentration of glucose in blood. Also considerable reduction of concentration of triglycerides, to a lesser extent — concentration of cholesterol, reduction of an aterogennost of lipids of plasma is noticed. At prolonged use of drug (about 6 months) improvement of a microcirculator blood-groove of an eye is noted.

Pharmacokinetics. After a single dose in 500 mg of drug Kadioaktiv Taurin, active ingredient taurine in 15-20 minutes is defined in blood, reaching a maximum in 1,5-2 hours. Completely drug is removed in a day.

Indications to use:

Drug is used in complex therapy:

• cardiovascular insufficiency of various etiology;
• intoxication caused by reception of cardiac glycosides;
• diabetes mellitus of 1 type;
• a diabetes mellitus 2 types, including with a moderate hypercholesterolemia.

Route of administration and doses:

Before use of drug to consult with the doctor. At heart failure Kardioaktiv Taurin accept inside 250-500 mg (1/2 — 1 tablet) 2 times a day in 20 minutes prior to food, a course of treatment — 30 days. The dose can be increased to 2-3 g (4-6 tablets) a day.

At intoxication cardiac glycosides — not less than 750 mg (1,5 tablets) a day.

At a diabetes mellitus of 1 type — on 500 mg (1 tablet) 2 times a day in combination with an insulin therapy within 3-6 months.

At a diabetes mellitus 2 types — on 500 mg (1 tablet) 2 times a day in combination with a dietotherapy or other hypoglycemic means for intake.

At a diabetes mellitus 2 types, including with a moderate hypercholesterolemia — on 500 mg (1 tablet) 2 times a day.

Features of use:

Use at pregnancy and during breastfeeding. Drug use Kardioaktiv Taurin is not recommended at pregnancy and during breastfeeding due to the lack of sufficient experience of a clinical use at this category of patients.

At complex treatment of heart failure, a diabetes mellitus, intoxication cardiac glycosides administration of drug is carried out under observation of the doctor.

Drug does not exert impact on performance of potentially dangerous types of activity demanding the increased concentration of attention and speed of psychotropic reactions (control of vehicles, work with moving mechanisms, work of the dispatcher, operator, etc.).

Side effects:

Allergic reactions to drug components are possible.

Interaction with other medicines:

The cardioasset Taurine can be applied with other medicines.

Taurine strengthens an inotropic effect of cardiac glycosides.

Contraindications:

- Heavy heart failure in a decompensation stage.
- Hypersensitivity to drug.
- The cardioasset Tuarin is not recommended for use for children aged up to 18 years in connection with insufficiency of data on efficiency and safety.

Precautionary measures at use. With care to apply the patient with heavy renal failures, at simultaneous use with cardiac glycosides, blockers of "slow" calcium channels (BMKK).

Overdose:

Data on overdose are absent.

Storage conditions:

To store at a temperature not above 25 °C. To store in the place, unavailable to children. A period of validity - 3 years. Not to apply after a period of validity.

Issue conditions:

Without recipe

Packaging:

Tablets of 500 mg. On 20 tablets in a blister strip packaging from a film of the polyvinyl chloride and flexible packaging made on the basis of aluminum foil. On 2 or 3 blister strip packagings together with the application instruction place in a pack from a cardboard.